PETRI DISH PERSPECTIVES

Manead Khin
  • 0.0 (0)
  • LIFE SCIENCES

Burma | ChicagoScientist 🥼🧪🔬Covering biotech, pharma, and healthcare companies shaping the world 🧬🏥🌎 Stream new episodes every THURSDAY! https://linktr.ee/maneadkhin #biotech #pharma #healthcare #podcast #petridishperspectives

  1. 5D AGO

    April 2026: Biotech & Pharma NEWS Roundup

    Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for April 2026! This month was dominated by a high-stakes pivot toward oral obesity treatments, a massive consolidation of precision oncology platforms like ADCs and radiopharmaceuticals, and a structural shift toward AI-native drug discovery and in-vivo genomic medicine. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

    11 min

  2. 6D AGO

    Episode 53: CAR-T Therapies

    Send us Fan Mail What if cancer treatment wasn’t a drug but a living, evolving system inside your body? In this episode, we break down one of the most revolutionary innovations in modern medicine: CAR-T cell therapy. From its origins in academic labs to billion-dollar acquisitions by companies like Gilead Sciences, Bristol Myers Squibb, and Novartis, CAR-T represents a fundamental shift, from treating disease to programming the immune system. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #CAR-T #CellTherapy #Biotech #Oncology #Immunotherapy #CRISPR #HealthcareInnovation #Pharma #BiotechPodcast #PetriDishPerspectives #PrecisionMedicine #CancerResearch #FutureOfMedicine Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

    25 min

  3. APR 23

    Episode 52: Daiichi Sankyo

    Send us Fan Mail In this episode of Petri Dish Perspectives: Biotech Unleashed, we break down the rise of Daiichi Sankyo, a company that quietly transformed itself from a cardiovascular powerhouse into one of the most dominant players in modern oncology. This isn’t your typical biotech story. There’s no overnight success, no single “eureka” moment. Instead, we trace a century-long evolution, from the pioneering work of Jokichi Takamine and the early days of enzyme therapeutics, to the merger that unified biological extraction with synthetic chemistry, and ultimately to the company’s bold, high-stakes bet on antibody-drug conjugates (ADCs). At the center of it all is Enhertu, the drug that shattered the traditional HER2 classification and redefined how we think about targeting cancer. We unpack how Daiichi Sankyo solved the ADC “linker problem,” engineered a platform with unmatched precision, and built a pipeline that’s now reshaping treatment across breast, lung, and gastric cancers. We also explore the strategic partnerships with AstraZeneca and Merck & Co., and what they signal about Daiichi Sankyo’s position as a true platform leader in the ADC gold rush. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Biotech #DaiichiSankyo #ADC #AntibodyDrugConjugates #Oncology #DrugDevelopment #Pharma #Enhertu #LifeSciences #BiotechPodcast #PetriDishPerspectives Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

    23 min

  4. APR 16

    Episode 51: ImmunoGen

    Send us Fan Mail In this episode of Petri Dish Perspectives: Biotech Unleashed, we dive into the 40+ year journey of ImmunoGen, a company that refused to give up on one of the most complex and misunderstood technologies in oncology: antibody-drug conjugates (ADCs). From its early days as a Dana-Farber spinout to decades of scientific setbacks, market skepticism, and near-collapse moments, ImmunoGen’s story is anything but linear. We explore how the company survived the “ADC dark ages,” built foundational technology through partnerships with giants like Genentech and Roche, and ultimately made the bold pivot from platform provider to full-fledged drug developer. If you want to understand how long it really takes to build a platform technology, why being early can be both a curse and a competitive advantage, and how persistence shapes success in biotech, this episode is for you. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Biotech #ImmunoGen #ADC #AntibodyDrugConjugates #Oncology #DrugDevelopment #Pharma #Biotechnology #CancerResearch #AbbVie #LifeSciences #BiotechPodcast #PetriDishPerspectives Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

    27 min

  5. APR 9

    Episode 50: Exact Sciences

    Send us Fan Mail In this episode of Petri Dish Perspectives, we’re dissecting the "Phoenix of Biotech." On March 23, 2026, the era of Exact Sciences as an independent company officially ended with its massive $23 billion acquisition by Abbott Laboratories. But the road to this exit wasn't paved with easy wins, it was forged in the wreckage of a "zombie" penny stock that almost didn't survive 2008. We take you through the high-stakes gamble of the DeeP-C trial, the behavioral economics behind the "Little Blue Box," and the strategic brilliance of the Genomic Health merger. We explore how Kevin Conroy turned a struggling Madison startup into a global diagnostic standard by mastering the one thing most biotechs ignore: the clinical workflow. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Biotech #AI #Pharma #LifeSciences #Podcast #PetriDishPerspectives #ExactSciences #AbbottLaboratories #BiotechStrategy #Oncology #Cologuard #LiquidBiopsy #PharmaNews #MAndA #CancerDetection #ScientificTranslator #Diagnostics #HealthTech #KevinConroy #BiotechPodcast Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

    24 min

  6. APR 2

    Episode 49: AI in Pharma / Biotech

    Send us Fan Mail In this episode, we explore the high-stakes reality of AI integration in the life sciences. We move past the speculative hype to examine the mechanical necessity of this shift, driven by soaring R&D costs and an explosion of biological data, and how the industry has transitioned from a "serendipity-based" model to one of predictive, generative biology. We break down the leaders of this revolution, comparing the "TechBio" pioneers like Insilico and Recursion with the massive infrastructure bets currently being made by Big Pharma giants. From the rise of autonomous, "closed-loop" labs to significant improvements in target discovery and preclinical timelines, we analyze where the technology is delivering measurable wins and where the "dirty data" gap still holds the industry back. Finally, we address the hard truths of this transition, including the recent wave of industry layoffs and the emergence of the "Scientific Translator" as the most vital role in the modern lab. We look ahead to a 2030 landscape defined by digital control arms and personalized medicine, offering essential lessons for any professional navigating the risks and rewards of an AI-integrated pipeline. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Biotech #AI #Pharma #LifeSciences #Podcast #PetriDishPerspectives Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

    25 min

  7. APR 1

    March 2026: Biotech & Pharma NEWS Roundup

    Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for March 2026! This month was dominated by by three massive themes: more AI integrations, M&A deals, and continued GLP-1 challenges. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

    13 min

  8. MAR 26

    Episode 48: Ginkgo Bioworks

    Send us Fan Mail In this episode of Petri Dish Perspectives, we unpack how Ginkgo Bioworks set out to industrialize biology. From its origins at MIT to building one of the most ambitious synthetic biology platforms in the world, we explore how the company positioned itself not as a traditional biotech, but as a “organism engineering foundry.” We break down Ginkgo’s unique business model, partnering with companies across pharma, agriculture, and consumer goods and how it generates value through cell programming, automation, and massive biological datasets. We also examine the company’s rapid rise, its high-profile SPAC debut, and the intense scrutiny that followed. Along the way, we dive into the science behind synthetic biology, the challenges of scaling engineered organisms, and the big question: can biology truly become an engineering discipline? If you want to understand the future of programmable biology and whether Ginkgo’s platform-first approach can reshape entire industries, this episode is for you. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Biotech #SyntheticBiology #GinkgoBioworks #Biotechnology #Bioengineering #DrugDevelopment #LifeSciences #Bioeconomy #Startup #SPAC #Innovation #PetriDishPerspectives Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

    24 min
See All (59)

About

Burma | ChicagoScientist 🥼🧪🔬Covering biotech, pharma, and healthcare companies shaping the world 🧬🏥🌎 Stream new episodes every THURSDAY! https://linktr.ee/maneadkhin #biotech #pharma #healthcare #podcast #petridishperspectives

Information

  • Creator
    Manead Khin
  • Years Active
    2025 - 2026
  • Episodes
    59
  • Rating
    Explicit
  • Copyright
    © 2026 PETRI DISH PERSPECTIVES
  • Show Website
    PETRI DISH PERSPECTIVES